Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233233 | 0.95 | HPGD (0.39) | MAPK1TSHRHSD17B10HPGDKDM4E | |
| SCHEMBL159767 | 0.93 | HPGD (0.42) | MAPK1TSHRHSD17B10HPGDKDM4E | |
| SCHEMBL8961761 | 0.91 | MAPT (0.31) | MAPTGAA | |
| SCHEMBL188699 | 0.81 | ADRB1 (0.50) | MAPK1TSHRHSD17B10HPGDKDM4E | |
| SCHEMBL1852924 | 0.81 | ADRA2C (0.44) | KDM4EALDH1A1MAPTGFERNCF1 | |
| SCHEMBL3213064 | 0.81 | AR (0.37) | ALDH1A1MAPTL3MBTL1GAA | |
| SCHEMBL189494 | 0.81 | LMNA (0.50) | TSHRHSD17B10HPGDKDM4EALDH1A1 | |
| SCHEMBL5655784 | 0.79 | KCNA3 (0.38) | MAPK1ALDH1A1MAPTL3MBTL1GAA | |
| SCHEMBL5423827 | 0.79 | KMT2A (0.50) | MAPK1TSHRHSD17B10HPGDALDH1A1 | |
| SCHEMBL5657586 | 0.78 | KDM4E (0.39) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104039799-B | As the macrocyclic amide of proteinase inhibitor | HOFFMAN-LA ROCHE LTD. (CH) | 2016-04-13 | — | — | CN | claimed |
| US-9290467-B2 | Cyclic amides | Hoffmann—La Roche Inc. (US) | 2016-03-22 | — | — | US | claimed |
| EP-2802591-B1 | MACROCYCLIC AMIDES AS PROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2016-03-16 | — | — | EP | claimed |
| EP-2802591-A1 | MACROCYCLIC AMIDES AS PROTEASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-11-19 | — | — | EP | claimed |
| CN-104039799-A | Macrocyclic amides as protease inhibitors | HOFFMANN LA ROCHE | 2014-09-10 | — | — | CN | claimed |
| EP-2424840-B1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-06 | — | — | EP | claimed |
| US-20130196965-A1 | CYCLIC AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2013-08-01 | — | — | US | claimed |
| WO-2013104613-A1 | MACROCYCLIC AMIDES AS PROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-18 | — | — | WO | claimed |
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | claimed |
| EP-2424840-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | claimed |
| WO-2010126811-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | claimed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | claimed |
| CN-1192018-C | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2005-03-09 | — | — | CN | claimed |
| CN-1353691-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-06-12 | — | — | CN | claimed |
| CN-1350520-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-05-22 | — | — | CN | claimed |
| US-11214573-B2 | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-01-04 | — | — | US | disclosed |
| US-11214573-B2 | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-01-04 | — | — | US | disclosed |
| CN-1192018-C | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2005-03-09 | — | — | CN | disclosed |
| CN-1353691-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-06-12 | — | — | CN | disclosed |
| CN-1350520-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196965-A1 | CYCLIC AMIDES | CCND2, CCKBR, CCNB1 | MAPK1 1742/4885TSHR 319/4885HSD17B10 1790/4885 |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | MAPK1 1967/4885TSHR 575/4885HSD17B10 2622/4885 |
| US-11214573-B2 | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | MAPK1 265/4885TSHR 1590/4885HSD17B10 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.